Switch theme
Sign up to access all valuation multiples
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
1998
2.2K+
LTM Revenue $683M
LTM EBITDA $44.2M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NeoGenomics has a last 12-month revenue of $683M and a last 12-month EBITDA of $44.2M.
In the most recent fiscal year, NeoGenomics achieved revenue of $661M and an EBITDA of -$1.5M.
NeoGenomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NeoGenomics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $592M | $661M | XXX | XXX | XXX |
| Gross Profit | $188M | $245M | XXX | XXX | XXX |
| Gross Margin | 32% | 37% | XXX | XXX | XXX |
| EBITDA | -$17.6M | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | -3% | 0% | XXX | XXX | XXX |
| Net Profit | -$144M | -$88.0M | XXX | XXX | XXX |
| Net Margin | -24% | -13% | XXX | XXX | XXX |
| Net Debt | $272M | $196M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, NeoGenomics's stock price is $10.
NeoGenomics has current market cap of $1.3B, and EV of $1.5B.
See NeoGenomics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.3B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, NeoGenomics has market cap of $1.3B and EV of $1.5B.
NeoGenomics's trades at 2.2x LTM EV/Revenue multiple, and 33.2x LTM EBITDA.
Analysts estimate NeoGenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for NeoGenomics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | -972.2x | XXX | XXX | XXX |
| P/E | -15.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -43.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNeoGenomics's NTM/LTM revenue growth is 12%
NeoGenomics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, NeoGenomics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate NeoGenomics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for NeoGenomics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -91% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 11% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 34% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 57% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NeoGenomics acquired XXX companies to date.
Last acquisition by NeoGenomics was XXXXXXXX, XXXXX XXXXX XXXXXX . NeoGenomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was NeoGenomics founded? | NeoGenomics was founded in 1998. |
| Where is NeoGenomics headquartered? | NeoGenomics is headquartered in United States of America. |
| How many employees does NeoGenomics have? | As of today, NeoGenomics has 2.2K+ employees. |
| Who is the CEO of NeoGenomics? | NeoGenomics's CEO is Mr. Anthony P. Zook. |
| Is NeoGenomics publicy listed? | Yes, NeoGenomics is a public company listed on NAS. |
| What is the stock symbol of NeoGenomics? | NeoGenomics trades under NEO ticker. |
| When did NeoGenomics go public? | NeoGenomics went public in 1996. |
| Who are competitors of NeoGenomics? | Similar companies to NeoGenomics include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of NeoGenomics? | NeoGenomics's current market cap is $1.3B |
| What is the current revenue of NeoGenomics? | NeoGenomics's last 12-month revenue is $683M. |
| What is the current EBITDA of NeoGenomics? | NeoGenomics's last 12-month EBITDA is $44.2M. |
| What is the current EV/Revenue multiple of NeoGenomics? | Current revenue multiple of NeoGenomics is 2.2x. |
| What is the current EV/EBITDA multiple of NeoGenomics? | Current EBITDA multiple of NeoGenomics is 33.2x. |
| What is the current revenue growth of NeoGenomics? | NeoGenomics revenue growth between 2023 and 2024 was 12%. |
| Is NeoGenomics profitable? | Yes, NeoGenomics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
